-
公开(公告)号：US08178560B2
公开(公告)日：2012-05-15
申请号：US12817773
申请日：2010-06-17
IPC: A61K31/44 , A01N43/40 , C07D401/00 , C07D417/00
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
Abstract translation: 式中的化合物：其中Ar1，Ar2，X，R3和m如本文所公开或其药学上可接受的盐（“环烯基烯基化合物”）; 包含有效量的环烯基烯基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的环烯基烯基化合物。
-
公开(公告)号：US20100331369A1
公开(公告)日：2010-12-30
申请号：US12817773
申请日：2010-06-17
IPC: A61K31/444 , A61P29/00
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
Abstract translation: 式中的化合物：其中Ar1，Ar2，X，R3和m如本文所公开或其药学上可接受的盐（“环烯基烯基化合物”）; 包含有效量的环烯基烯基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的环烯基烯基化合物。
-
公开(公告)号：US08637548B2
公开(公告)日：2014-01-28
申请号：US12886901
申请日：2010-09-21
IPC: A01N43/40 , A61K31/44 , C07D213/22 , C07D401/00 , C07D405/00 , C07D409/00 , C07D411/00
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
Abstract translation: 式中的化合物：其中Ar1，Ar2，X，R3和m如本文所公开或其药学上可接受的盐（“环烯基烯基化合物”）; 包含有效量的环烯基烯基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的环烯基烯基化合物。
-
公开(公告)号：US20110071192A1
公开(公告)日：2011-03-24
申请号：US12886901
申请日：2010-09-21
IPC: A61K31/444 , C07D401/04 , C12N5/00 , A61P29/00 , C07D417/14
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
Abstract translation: 式中的化合物：其中Ar1，Ar2，X，R3和m如本文所公开或其药学上可接受的盐（“环烯基烯基化合物”）; 包含有效量的环烯基烯基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的环烯基烯基化合物。
-
公开(公告)号：US07776861B2
公开(公告)日：2010-08-17
申请号：US11338502
申请日：2006-01-23
IPC: A61K31/497 , A61K31/44 , A61K31/635 , A01N43/40 , A01N43/56 , C07D401/00 , C07D417/00
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
Abstract translation: 式中的化合物：其中Ar1，Ar2，X，R3和m如本文所公开或其药学上可接受的盐（“环烯基烯基化合物”）; 包含有效量的环烯基烯基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的环烯基烯基化合物。
-
Patent Agency Ranking
公开(公告)号：US20060128717A1
公开(公告)日：2006-06-15
申请号：US11338502
申请日：2006-01-23
IPC: A61K31/506 , A61K31/501 , A61K31/497 , A61K31/444 , C07D417/14 , C07D413/14 , C07D403/14 , C07D401/14
CPC classification number: A61K31/444 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Tetrahydropiperidyl Compound”); compositions comprising an effective amount of a Tetrahydropiperidyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Tetrahydropiperidyl Compound are disclosed herein.
Abstract translation: 下式的化合物：其中Ar 1，Ar 2，X，R 3和m如本文所公开或其药学上可接受的盐 （“四氢哌啶基化合物”）; 包含有效量的四氢哌啶基化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，受限制 脑功能，亨廷顿氏舞蹈病，肌萎缩性侧索硬化症，痴呆症，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的四氢哌啶基化合物。
-
公开(公告)号：US11110176B2
公开(公告)日：2021-09-07
申请号：US15821671
申请日：2017-11-22
Applicant: Xin Wen
Inventor： Xin Wen
Abstract: Embodiments of the disclosure pertain to compositions containing (i) one or more non-antifreeze proteins or cell components or cells and (ii) one or more antifreeze proteins (AFPs), mimetics thereof, and/or analogs thereof, and a method of stabilizing a biologic (e.g., a protein, microbe, cell component or cell) against temperature stress and aggregation. The AFP may be selected from known antifreeze polypeptides and antifreeze peptides, analogs and mimetics of antifreeze proteins, active fragments of such antifreeze proteins, polypeptide and peptide mimetics, antifreeze peptoids and polymers, and combinations thereof. The non-antifreeze protein, cell component or cell comprises a known protein, cell component or cell used in the pharmaceutical, medical, agricultural, veterinary and/or food industry(ies). The AFP protects the function of the non-antifreeze protein, microbe(s), cell component(s) or cell(s) under temperature stress (e.g., a temperature of −20-60° C.).
-
公开(公告)号：US08082053B2
公开(公告)日：2011-12-20
申请号：US11935320
申请日：2007-11-05
Applicant: Xin Wen , Russ Ennio Muzzolini , Jeff D. Boone
Inventor： Xin Wen , Russ Ennio Muzzolini , Jeff D. Boone
IPC: G06F19/00
CPC classification number: G05B19/41865 , G05B2219/25182 , G05B2219/32263 , G06Q10/06 , Y02P90/20
Abstract: An automated manufacturing system comprises a computer processing system and a plurality of consolidation systems. The computer processing system receives information on product subbatches and product packages and consolidation status information to produce consolidation assignment information, each product package comprising one or more product subbatches. The consolidation systems receive the product subbatches in accordance to the consolidation assignment information and consolidate the product subbatches into product packages, wherein the status of the consolidation systems are tracked and the consolidation status information is sent to the computer processing system.
Abstract translation: 自动化制造系统包括计算机处理系统和多个合并系统。 计算机处理系统接收关于产品子批和产品包和合并状态信息的信息以产生合并分配信息，每个产品包包括一个或多个产品子批。 整合系统根据合并分配信息接收产品子批次，并将产品子批次合并到产品包中，其中跟踪合并系统的状态，并将合并状态信息发送到计算机处理系统。
-
公开(公告)号：US20090287585A1
公开(公告)日：2009-11-19
申请号：US12476886
申请日：2009-06-02
Applicant: Peter Charles Elarde , Patrick C. Teo , Russ Ennio Muzzolini , Jeannine Marie Smith , Xin Wen
Inventor： Peter Charles Elarde , Patrick C. Teo , Russ Ennio Muzzolini , Jeannine Marie Smith , Xin Wen
CPC classification number: B42D5/04 , B42D15/045 , G06Q30/0601
Abstract: A method for producing a gift card for a gift imaging product, comprises receiving an order of the gift imaging product from a user, producing the gift imaging product, producing the gift card by the user for the gift imaging product; and consolidating the gift card with the gift imaging product into one package.
Abstract translation: 一种用于制作礼物成像产品的礼品卡的方法，包括从用户接收礼品成像产品的订单，产生礼品成像产品，由用户为礼物成像产品生产礼品卡; 并将礼品卡与礼品成像产品整合成一个包装。
-
公开(公告)号：US20080288521A1
公开(公告)日：2008-11-20
申请号：US11935320
申请日：2007-11-05
Applicant: Xin Wen , Russ Ennio Muzzolini , Jeff D. Boone
Inventor： Xin Wen , Russ Ennio Muzzolini , Jeff D. Boone
IPC: G06F17/30
CPC classification number: G05B19/41865 , G05B2219/25182 , G05B2219/32263 , G06Q10/06 , Y02P90/20
Abstract: An automated manufacturing system comprises a computer processing system and a plurality of consolidation systems. The computer processing system receives information on product subbatches and product packages and consolidation status information to produce consolidation assignment information, each product package comprising one or more product subbatches. The consolidation systems receive the product subbatches in accordance to the consolidation assignment information and consolidate the product subbatches into product packages, wherein the status of the consolidation systems are tracked and the consolidation status information is sent to the computer processing system.
Abstract translation: 自动化制造系统包括计算机处理系统和多个合并系统。 计算机处理系统接收关于产品子批和产品包和合并状态信息的信息以产生合并分配信息，每个产品包包括一个或多个产品子批。 整合系统根据合并分配信息接收产品子批次，并将产品子批次合并到产品包中，其中跟踪合并系统的状态，并将合并状态信息发送到计算机处理系统。
-
-
-
-
-
-
-
-
-
Search Results
159
records
(took 0.036 seconds)
